Cargando…

Computational Drug Target Screening through Protein Interaction Profiles

The development of computational methods to discover novel drug-target interactions on a large scale is of great interest. We propose a new method for virtual screening based on protein interaction profile similarity to discover new targets for molecules, including existing drugs. We calculated Targ...

Descripción completa

Detalles Bibliográficos
Autores principales: Vilar, Santiago, Quezada, Elías, Uriarte, Eugenio, Costanzi, Stefano, Borges, Fernanda, Viña, Dolores, Hripcsak, George
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5109486/
https://www.ncbi.nlm.nih.gov/pubmed/27845365
http://dx.doi.org/10.1038/srep36969
_version_ 1782467550580310016
author Vilar, Santiago
Quezada, Elías
Uriarte, Eugenio
Costanzi, Stefano
Borges, Fernanda
Viña, Dolores
Hripcsak, George
author_facet Vilar, Santiago
Quezada, Elías
Uriarte, Eugenio
Costanzi, Stefano
Borges, Fernanda
Viña, Dolores
Hripcsak, George
author_sort Vilar, Santiago
collection PubMed
description The development of computational methods to discover novel drug-target interactions on a large scale is of great interest. We propose a new method for virtual screening based on protein interaction profile similarity to discover new targets for molecules, including existing drugs. We calculated Target Interaction Profile Fingerprints (TIPFs) based on ChEMBL database to evaluate drug similarity and generated new putative compound-target candidates from the non-intersecting targets in each pair of compounds. A set of drugs was further studied in monoamine oxidase B (MAO-B) and cyclooxygenase-1 (COX-1) enzyme through molecular docking and experimental assays. The drug ethoxzolamide and the natural compound piperlongumine, present in Piper longum L, showed hMAO-B activity with IC(50) values of 25 and 65 μM respectively. Five candidates, including lapatinib, SB-202190, RO-316233, GW786460X and indirubin-3′-monoxime were tested against human COX-1. Compounds SB-202190 and RO-316233 showed a IC(50) in hCOX-1 of 24 and 25 μM respectively (similar range as potent inhibitors such as diclofenac and indomethacin in the same experimental conditions). Lapatinib and indirubin-3′-monoxime showed moderate hCOX-1 activity (19.5% and 28% of enzyme inhibition at 25 μM respectively). Our modeling constitutes a multi-target predictor for large scale virtual screening with potential in lead discovery, repositioning and drug safety.
format Online
Article
Text
id pubmed-5109486
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-51094862016-11-25 Computational Drug Target Screening through Protein Interaction Profiles Vilar, Santiago Quezada, Elías Uriarte, Eugenio Costanzi, Stefano Borges, Fernanda Viña, Dolores Hripcsak, George Sci Rep Article The development of computational methods to discover novel drug-target interactions on a large scale is of great interest. We propose a new method for virtual screening based on protein interaction profile similarity to discover new targets for molecules, including existing drugs. We calculated Target Interaction Profile Fingerprints (TIPFs) based on ChEMBL database to evaluate drug similarity and generated new putative compound-target candidates from the non-intersecting targets in each pair of compounds. A set of drugs was further studied in monoamine oxidase B (MAO-B) and cyclooxygenase-1 (COX-1) enzyme through molecular docking and experimental assays. The drug ethoxzolamide and the natural compound piperlongumine, present in Piper longum L, showed hMAO-B activity with IC(50) values of 25 and 65 μM respectively. Five candidates, including lapatinib, SB-202190, RO-316233, GW786460X and indirubin-3′-monoxime were tested against human COX-1. Compounds SB-202190 and RO-316233 showed a IC(50) in hCOX-1 of 24 and 25 μM respectively (similar range as potent inhibitors such as diclofenac and indomethacin in the same experimental conditions). Lapatinib and indirubin-3′-monoxime showed moderate hCOX-1 activity (19.5% and 28% of enzyme inhibition at 25 μM respectively). Our modeling constitutes a multi-target predictor for large scale virtual screening with potential in lead discovery, repositioning and drug safety. Nature Publishing Group 2016-11-15 /pmc/articles/PMC5109486/ /pubmed/27845365 http://dx.doi.org/10.1038/srep36969 Text en Copyright © 2016, The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Article
Vilar, Santiago
Quezada, Elías
Uriarte, Eugenio
Costanzi, Stefano
Borges, Fernanda
Viña, Dolores
Hripcsak, George
Computational Drug Target Screening through Protein Interaction Profiles
title Computational Drug Target Screening through Protein Interaction Profiles
title_full Computational Drug Target Screening through Protein Interaction Profiles
title_fullStr Computational Drug Target Screening through Protein Interaction Profiles
title_full_unstemmed Computational Drug Target Screening through Protein Interaction Profiles
title_short Computational Drug Target Screening through Protein Interaction Profiles
title_sort computational drug target screening through protein interaction profiles
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5109486/
https://www.ncbi.nlm.nih.gov/pubmed/27845365
http://dx.doi.org/10.1038/srep36969
work_keys_str_mv AT vilarsantiago computationaldrugtargetscreeningthroughproteininteractionprofiles
AT quezadaelias computationaldrugtargetscreeningthroughproteininteractionprofiles
AT uriarteeugenio computationaldrugtargetscreeningthroughproteininteractionprofiles
AT costanzistefano computationaldrugtargetscreeningthroughproteininteractionprofiles
AT borgesfernanda computationaldrugtargetscreeningthroughproteininteractionprofiles
AT vinadolores computationaldrugtargetscreeningthroughproteininteractionprofiles
AT hripcsakgeorge computationaldrugtargetscreeningthroughproteininteractionprofiles